BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 15064718)

  • 1. Phosphorylation and ubiquitination of oncogenic mutants of beta-catenin containing substitutions at Asp32.
    Al-Fageeh M; Li Q; Dashwood WM; Myzak MC; Dashwood RH
    Oncogene; 2004 Jun; 23(28):4839-46. PubMed ID: 15064718
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterisation of the phosphorylation of beta-catenin at the GSK-3 priming site Ser45.
    Hagen T; Vidal-Puig A
    Biochem Biophys Res Commun; 2002 Jun; 294(2):324-8. PubMed ID: 12051714
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutational analysis of Ctnnb1 and Apc in tumors from rats given 1,2-dimethylhydrazine or 2-amino-3-methylimidazo[4,5-f]quinoline: mutational 'hotspots' and the relative expression of beta-catenin and c-jun.
    Blum CA; Tanaka T; Zhong X; Li Q; Dashwood WM; Pereira C; Xu M; Dashwood RH
    Mol Carcinog; 2003 Apr; 36(4):195-203. PubMed ID: 12669311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation of the {beta}-catenin/T-cell-specific transcription factor/lymphoid enhancer factor-1 pathway by plasminogen activators in ECV304 carcinoma cells.
    Maupas-Schwalm F; Robinet C; Augé N; Thiers JC; Garcia V; Cambus JP; Salvayre R; Nègre-Salvayre A
    Cancer Res; 2005 Jan; 65(2):526-32. PubMed ID: 15695395
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Threonine 41 in beta-catenin serves as a key phosphorylation relay residue in beta-catenin degradation.
    Wu G; He X
    Biochemistry; 2006 Apr; 45(16):5319-23. PubMed ID: 16618120
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual alterations in casein kinase I-epsilon and GSK-3beta modulate beta-catenin stability in hyperproliferating colonic epithelia.
    Umar S; Wang Y; Morris AP; Sellin JH
    Am J Physiol Gastrointest Liver Physiol; 2007 Feb; 292(2):G599-607. PubMed ID: 17053159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduction of beta-catenin/T-cell transcription factor signaling by aspirin and indomethacin is caused by an increased stabilization of phosphorylated beta-catenin.
    Dihlmann S; Klein S; Doeberitz Mv Mv
    Mol Cancer Ther; 2003 Jun; 2(6):509-16. PubMed ID: 12813129
    [TBL] [Abstract][Full Text] [Related]  

  • 8. beta-Catenin mutation in rat colon tumors initiated by 1,2-dimethylhydrazine and 2-amino-3-methylimidazo[4,5-f]quinoline, and the effect of post-initiation treatment with chlorophyllin and indole-3-carbinol.
    Blum CA; Xu M; Orner GA; Fong AT; Bailey GS; Stoner GD; Horio DT; Dashwood RH
    Carcinogenesis; 2001 Feb; 22(2):315-20. PubMed ID: 11181454
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulation of S33/S37 phosphorylated beta-catenin in normal and transformed cells.
    Sadot E; Conacci-Sorrell M; Zhurinsky J; Shnizer D; Lando Z; Zharhary D; Kam Z; Ben-Ze'ev A; Geiger B
    J Cell Sci; 2002 Jul; 115(Pt 13):2771-80. PubMed ID: 12077367
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus manipulates the activity of glycogen synthase kinase-3beta.
    Fujimuro M; Hayward SD
    J Virol; 2003 Jul; 77(14):8019-30. PubMed ID: 12829841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Axin, a negative regulator of the Wnt signaling pathway, forms a complex with GSK-3beta and beta-catenin and promotes GSK-3beta-dependent phosphorylation of beta-catenin.
    Ikeda S; Kishida S; Yamamoto H; Murai H; Koyama S; Kikuchi A
    EMBO J; 1998 Mar; 17(5):1371-84. PubMed ID: 9482734
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oncogenic K-ras stimulates Wnt signaling in colon cancer through inhibition of GSK-3beta.
    Li J; Mizukami Y; Zhang X; Jo WS; Chung DC
    Gastroenterology; 2005 Jun; 128(7):1907-18. PubMed ID: 15940626
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The aurora kinase A regulates GSK-3beta in gastric cancer cells.
    Dar AA; Belkhiri A; El-Rifai W
    Oncogene; 2009 Feb; 28(6):866-75. PubMed ID: 19060929
    [TBL] [Abstract][Full Text] [Related]  

  • 14. beta-catenin is a target for the ubiquitin-proteasome pathway.
    Aberle H; Bauer A; Stappert J; Kispert A; Kemler R
    EMBO J; 1997 Jul; 16(13):3797-804. PubMed ID: 9233789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alterations of beta-catenin and Tcf-4 instead of GSK-3beta contribute to activation of Wnt pathway in hepatocellular carcinoma.
    Cui J; Zhou X; Liu Y; Tang Z; Romeih M
    Chin Med J (Engl); 2003 Dec; 116(12):1885-92. PubMed ID: 14687479
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A GSK3beta phosphorylation site in axin modulates interaction with beta-catenin and Tcf-mediated gene expression.
    Jho Eh; Lomvardas S; Costantini F
    Biochem Biophys Res Commun; 1999 Dec; 266(1):28-35. PubMed ID: 10581160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Axin-mediated CKI phosphorylation of beta-catenin at Ser 45: a molecular switch for the Wnt pathway.
    Amit S; Hatzubai A; Birman Y; Andersen JS; Ben-Shushan E; Mann M; Ben-Neriah Y; Alkalay I
    Genes Dev; 2002 May; 16(9):1066-76. PubMed ID: 12000790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phosphorylation of beta-catenin by cyclic AMP-dependent protein kinase stabilizes beta-catenin through inhibition of its ubiquitination.
    Hino S; Tanji C; Nakayama KI; Kikuchi A
    Mol Cell Biol; 2005 Oct; 25(20):9063-72. PubMed ID: 16199882
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dysregulation of glycogen synthase kinase-3beta signaling in hepatocellular carcinoma cells.
    Desbois-Mouthon C; Blivet-Van Eggelpoël MJ; Beurel E; Boissan M; Delélo R; Cadoret A; Capeau J
    Hepatology; 2002 Dec; 36(6):1528-36. PubMed ID: 12447879
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression and characterization of GSK-3 mutants and their effect on beta-catenin phosphorylation in intact cells.
    Hagen T; Di Daniel E; Culbert AA; Reith AD
    J Biol Chem; 2002 Jun; 277(26):23330-5. PubMed ID: 11967263
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.